---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Gastrointestinal and nutritional management"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Gastrointestinal and nutritional management. Topics: Consensus guideline: constipation and gastro-oesophageal reflux; Consensus guideline: poor weight gain, prolonged feeding, and swallowing difficulties; Expert recommendations: proactive management of gastrointestinal comorbidities; Real-world management by US physicians: constipation, growth, and reflux; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/gastrointestinal-and-nutritional-management"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Gastrointestinal and nutritional management

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Gastrointestinal and Nutritional Management

<a id="topic-2.2.2.1.3-1"></a>

### Consensus guideline: constipation and gastro-oesophageal reflux

> “Laxatives (polyethylene glycol, magnesium hydroxide, glycerin or bisacodyl suppositories) are often part of long-term treatment with a goal of one soft bowel movement per day.”
> “Proton pump inhibitor or H2 blockers are used empirically. Referral to gastroenterologist may be necessary to rule out complications such as oesophagitis, ulcer, strictures or Barrett’s oesophagus.”
> “Gall bladder dysfunction, screened by abdominal ultrasound, should be considered. Referral to surgery for cholecystectomy may be necessary for symptomatic gallstones or biliary dyskinesia.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.3-2"></a>

### Consensus guideline: poor weight gain, prolonged feeding, and swallowing difficulties

> “Fatigue and irritability may be signs that dietary requirements are not being met; consider energy dense foods (oils, syrups, avocado), and gastroenterologist and nutrition consults. Gastrostomy button may be needed to maintain growth; counsel families that use of a gastrostomy button does not preclude oral feeding as long as oral feeding is safe.”
> “Long feeding times (more than 30 min) can affect quality of life for patient and family; this may be an indication that a gastrostomy button is needed.”
> “In some cases, thickeners for liquids may be helpful to prevent aspiration versus need for a gastrostomy button.”
> “Consider nutrition-related laboratory screening (yearly): complete blood count, electrolyte panel, 25-OH vitamin D, fasting lipids.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.3-3"></a>

### Expert recommendations: proactive management of gastrointestinal comorbidities

> “Although gastrointestinal (GI) comorbidities are experienced by over 90% of individuals with Rett syndrome (RTT), a neurodevelopmental disorder associated with mutations in the MECP2 gene, many neurologists and pediatricians do not rank the management of these comorbidities among the most important treatment goals for RTT.”
> “The authors recommend a proactive approach to management of symptomatic GI comorbidities and drug-associated symptoms in RTT to enhance drug tolerance and improve the quality of life of affected individuals.”

Source: [Motil et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38869952/)

<a id="topic-2.2.2.1.3-4"></a>

### Real-world management by US physicians: constipation, growth, and reflux

> “For the treatment of constipation, neurologists most commonly referred patients to a dietician or to a gastroenterologist (57.1% each), while pediatricians were most likely to provide dietary recommendation (91.3%), refer to a dietician (78.3%), and prescribe laxatives (69.6%).”
> “Among the 10 pediatricians who responded, all (100%) prescribed anti-reflux medication, 8 (80%) referred to a dietician, and 7 (70%) provided dietary recommendations and advice.”
> “Management of GI issues was ranked among the five most important treatment goals by 3 (5.9%) neurologists and 4 (8.2%) pediatricians surveyed.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.2.1.3-5"></a>

### Gastrostomy: utilization, weight gain, and family satisfaction in an Australian population cohort

> “Sixty-six females (28.8%) had a gastrostomy”
> “Weight-for-age z-scores increased by 0.86 (95% CI 0.41, 1.31) approximately 2 years after surgery.”
> “Families were satisfied with gastrostomy and felt less anxious about the care of their child.”

Source: [Downs et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603139/)

<a id="topic-2.2.2.1.3-6"></a>

### Gastrostomy: body mass index and mortality in a longitudinal cohort

> “Nearly one-third (30.3%) of the cases underwent gastrostomy placement.”
> “Nevertheless, among those at risk of suboptimal weight, the all-cause mortality rate was greater in those who had gastrostomy placement compared with those who had not (hazard ratio 4.07, 95% CI 1.96-8.45).”
> “Gastrostomy placement was associated with improvement in BMI in females with Rett syndrome, but its long-term impact on individuals and their families is unclear.”

Source: [Wong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941161/)

<a id="topic-2.2.2.1.3-7"></a>

### Multidisciplinary clinic cohort: aperients and gastrostomy

> “Constipation was reported in 65% and all required specific treatment with aperients.”
> “Gastrostomy feeding tube placement was required for 24 (23.3%) girls at a mean age of 8 years (SD 4.2 years).”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

<a id="topic-2.2.2.1.3-8"></a>

### Systematic review: enteral feeding utilization across studies

> “Eighteen studies examined assisted interventions, showing enteral feeding utilization rates from 2.0% to 52.0%.”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
